文献速递肝病消化道肿瘤与早癌

丙肝治愈后MASLD患者:脂肪变分级与心血管代谢负担对肝癌风险的影响

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Gut · 2026-01-20

该研究纳入700例丙肝治愈后接受半年一次肝癌监测的MASLD患者,按受控衰减参数分为S1-S3脂肪变分级。结果显示累积肝癌发生率在不同脂肪变分级间有显著差异(p=0.035),S3 vs S1的aHR为2.15(95%CI 1.25-3.69),糖尿病前期或2型糖尿病aHR为2.33(95%CI 1.38-3.94)。整体心血管代谢负担与肝癌风险无关。

要点

  • 晚期肝脂肪变(S3)与丙肝治愈后MASLD患者肝癌风险独立相关
  • 糖尿病前期或2型糖尿病是肝癌风险的独立预测因素
  • 整体心血管代谢负担而非单一因素,与肝癌风险无显著关联

核心结论

  • 晚期肝脂肪变和血糖异常,而非整体心血管代谢负担,与丙肝治愈后肝癌风险独立相关。

研究设计与样本

  • enrolling 700 patients who underwent biannual HCC surveillance after HCV cure.

主要发现

  • Cumulative HCC incidence differed significantly across steatosis grades (p=0.035) but not across cardiometabolic burdens (p=0.62).
  • S3 vs S1: aHR 2.15, 95% CI 1.25 to 3.69, p=0.005.
  • Pre-diabetes or type 2 diabetes: aHR 2.33, 95% CI 1.38 to 3.94, p=0.002.

关键数值与推荐

  • Steatosis graded by controlled attenuation parameter cut-offs: 248-267 dB/m (S1), 268-279 dB/m (S2), ≥280 dB/m (S3).
  • Fine-Gray subdistribution hazard models confirmed associations.

临床怎么用

  • 对丙肝治愈后MASLD患者,应关注肝脂肪变分级和血糖状态以评估肝癌风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coexistence of metabolic dysfunction-associated steatotic liver disease (MASLD) increases hepatocellular carcinoma (HCC) risk after HCV cure. OBJECTIVE: The specific impacts of steatosis grade and cardiometabolic burden on HCC risk among patients with MASLD remain unclear. DESIGN: We enrolled 700 patients who underwent biannual HCC surveillance after HCV cure. Steatosis was graded by vibration-controlled transient elastography using controlled attenuation parameter cut-offs of 248-267, 268-279 and ≥280 dB/m, corresponding to S1, S2 and S3, respectively. Cardiometabolic risk factors (CMRFs) were assessed at the time of viral cure. Cumulative HCC incidence was compared across steatosis grades and cardiometabolic burdens using the log-rank test. Multivariable Cox proportional hazards models with Akaike Information Criterion-based selection evaluated the effects of steatosis grade, cardiometabolic burden and individual CMRFs on HCC risk, expressed as adjusted HRs (aHRs) with 95% CIs. Fine-Gray subdistribution hazard models were used for sensitivity analyses. RESULTS: Cumulative HCC incidence differed significantly across steatosis grades (p=0.035) but not across cardiometabolic burdens (p=0.62). In multivariable analysis adjusted for age, sex, liver stiffness and alpha-fetoprotein, advanced steatosis remained independently associated with HCC risk (S3 vs S1: aHR 2.15, 95% CI 1.25 to 3.69, p=0.005). Among individual CMRFs, pre-diabetes or type 2 diabetes was significantly associated with HCC risk (aHR 2.33, 95% CI 1.38 to 3.94, p=0.002). Fine-Gray analyses confirmed these associations. CONCLUSION: Advanced hepatic steatosis and glycaemic abnormalities, rather than overall cardiometabolic burden, are independently associated with increased HCC risk after HCV cure.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Chang YP, Chen YC, Cheng PN, et al. Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2026. PMID: 41558815. doi:10.1136/gutjnl-2025-337275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。